Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Autologous Natural Killer Cell-enrichment for Immune Cell Therapy: Preclinical Setting Phase, Shiraz Experience.

Iranian journal of allergy, asthma, and immunology - 17 Apr 2021

Rezaeifard Somayeh, Heike Yuji, Masuyama Jun-Ichi, Rezvani Alireaz, Vojdani Reza, Erfani Nasrollah

Abstract excerpt

Natural killer (NK) cell therapy has proven to be a promising approach for the treatment of malignancies. Osaki method for ex-vivo autologous NK cell expansion has been recently introduced in Japan. To start clinical trial phase I at Shiraz University of Medical Sciences in collaboration with the Japanese group, this preclinical setting study aimed to evaluate the proliferative efficacy of the method, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B-Lymphocytes
Share to Cell- and Tissue-Based Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Survival

Share to Fluoresceins

Share to Interferon-gamma

Share to K562 Cells

Share to Killer Cells, Natural

Share to T-Lymphocytes

Source

Identifiers

PMID: 33904681

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Autologous Natural Killer Cell-enrichment for Immune Cell Therapy: Preclinical Setting Phase, Shiraz Experience.PMID 33904681Read ↗

Ex vivo expansion of natural killer cells from human peripheral blood mononuclear cells co-stimulated with anti-CD3 and anti-CD52 monoclonal antibodies.Semantic proximity Read ↗

Sufficiently activated mature natural killer cells derived from peripheral blood mononuclear cells substantially enhance antitumor activitySemantic proximity Read ↗

Dark NKnight rising: a current perspective on NK cell and CAR-NK cell therapySemantic proximity Read ↗

Supercharged NK Cells Are a Unique Population of Cells Based on Transcriptomic, Single-Cell RNAseq, Proteomic, and Functional Characteristics; Comparison with Other NK Cell SubpopulationsSemantic proximity Read ↗

Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors.Semantic proximity Read ↗

Automated and closed clinical-grade manufacturing protocol produces potent NK cells against neuroblastoma cells and AML blastsSemantic proximity Read ↗

Enhancement of NK cell proliferation by activation pre-processing of autologous feeder cell before irradiationSemantic proximity Read ↗

Natural killer cell‐based immunotherapy in cancer: current insights and future prospectsSemantic proximity Read ↗

A Novel Feeder cell based on 4-1BBL and Membrane-bound IL-21/ IL-15 Induce Highly Expansion and Anti-tumor Effect of Natural Killer CellsSemantic proximity Read ↗

Bringing natural killer cells to the clinic: ex vivo manipulationSemantic proximity Read ↗

Directed Differentiation of Mobilized Hematopoietic Stem and Progenitor Cells into Functional NK cells with Enhanced Antitumor Activity.Semantic proximity Read ↗

Expanded adaptive NKG2C+ NK cells exhibit potent ADCC and functional responses against HBV-infected hepatoma cell linesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.